🫁 #ASCO26 #LungCancer
WU-KONG28: 1L Sunvozertinib in EGFR exon20ins NSCLC
Compared to carbo/pemetrexed, sunvozertinib improved:
🔹mPFS 10.3 vs 7.5 mo (HR 0.65; 95% CI, 0.50 to 0.85)
🔹12mo PFS: 46.1% vs 26.7%
🔹ORR: 58.9% vs 31.1%
🔹mDOR 11.2 vs 7.1 mo
⬆️G3 or higher AEs: 75.5% vs 56.7%
Looking forward to seeing the presentation & discussion today during the metastatic NSCLC Oral Abstracts Session.
Obvious concerns re: comparator arm and how would sunvozertinib perform against current SOC, chemo + amivantamab?
and most importantly, when will this drug be available in the US?
🔗: nejm.org/doi/pdf/10.105…
@ASCO #LCSM @OncodailyLung @OncBrothers @OncoAlertView quoted post on X
